Abstract
Women with polycystic ovary syndrome (PCOS) have a myriad of phenotypic and clinical features that may guide therapeutic options for metabolic protection and ovulation induction. The use of metformin may prove beneficial in a subset of the population of women with PCOS. Hyperinsulinemia, as demonstrated by elevated insulin levels on a 2-hour 75-g load glucose tolerance test, is an important parameter in deciding whether or not to initiate metformin therapy to women with PCOS with the hope of preventing or delaying the onset of type 2 diabetes mellitus (DM). Cardiovascular risk factors including markers of subclinical inflammation, and dyslipidemia may also be improved by metformin therapy. For ovulation induction, metformin is not as effective as clomiphene citrate as first-line therapy for women with PCOS. There are no clear data to suggest that metformin reduces pregnancy loss or improves pregnancy outcome in PCOS, and it is currently recommended that metformin be discontinued with the first positive pregnancy test result, unless there are other medical indications (eg, type 2 DM). This review addresses practical management guidelines for the uses of metformin in women with PCOS.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 596-609 |
| Number of pages | 14 |
| Journal | American Journal of Obstetrics and Gynecology |
| Volume | 199 |
| Issue number | 6 |
| DOIs | |
| State | Published - Dec 1 2008 |
Fingerprint
Keywords
- infertility
- insulin resistance
- metformin
- polycystic ovary syndrome
- pregnancy
ASJC Scopus subject areas
- Obstetrics and Gynecology
Cite this
Use of metformin in polycystic ovary syndrome. / Mathur, Ruchi; Alexander, Carolyn J.; Yano, Jacqueline; Trivax, Bradley; Azziz, Ricardo.
In: American Journal of Obstetrics and Gynecology, Vol. 199, No. 6, 01.12.2008, p. 596-609.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Use of metformin in polycystic ovary syndrome
AU - Mathur, Ruchi
AU - Alexander, Carolyn J.
AU - Yano, Jacqueline
AU - Trivax, Bradley
AU - Azziz, Ricardo
PY - 2008/12/1
Y1 - 2008/12/1
N2 - Women with polycystic ovary syndrome (PCOS) have a myriad of phenotypic and clinical features that may guide therapeutic options for metabolic protection and ovulation induction. The use of metformin may prove beneficial in a subset of the population of women with PCOS. Hyperinsulinemia, as demonstrated by elevated insulin levels on a 2-hour 75-g load glucose tolerance test, is an important parameter in deciding whether or not to initiate metformin therapy to women with PCOS with the hope of preventing or delaying the onset of type 2 diabetes mellitus (DM). Cardiovascular risk factors including markers of subclinical inflammation, and dyslipidemia may also be improved by metformin therapy. For ovulation induction, metformin is not as effective as clomiphene citrate as first-line therapy for women with PCOS. There are no clear data to suggest that metformin reduces pregnancy loss or improves pregnancy outcome in PCOS, and it is currently recommended that metformin be discontinued with the first positive pregnancy test result, unless there are other medical indications (eg, type 2 DM). This review addresses practical management guidelines for the uses of metformin in women with PCOS.
AB - Women with polycystic ovary syndrome (PCOS) have a myriad of phenotypic and clinical features that may guide therapeutic options for metabolic protection and ovulation induction. The use of metformin may prove beneficial in a subset of the population of women with PCOS. Hyperinsulinemia, as demonstrated by elevated insulin levels on a 2-hour 75-g load glucose tolerance test, is an important parameter in deciding whether or not to initiate metformin therapy to women with PCOS with the hope of preventing or delaying the onset of type 2 diabetes mellitus (DM). Cardiovascular risk factors including markers of subclinical inflammation, and dyslipidemia may also be improved by metformin therapy. For ovulation induction, metformin is not as effective as clomiphene citrate as first-line therapy for women with PCOS. There are no clear data to suggest that metformin reduces pregnancy loss or improves pregnancy outcome in PCOS, and it is currently recommended that metformin be discontinued with the first positive pregnancy test result, unless there are other medical indications (eg, type 2 DM). This review addresses practical management guidelines for the uses of metformin in women with PCOS.
KW - infertility
KW - insulin resistance
KW - metformin
KW - polycystic ovary syndrome
KW - pregnancy
UR - http://www.scopus.com/inward/record.url?scp=57149142767&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=57149142767&partnerID=8YFLogxK
U2 - 10.1016/j.ajog.2008.09.010
DO - 10.1016/j.ajog.2008.09.010
M3 - Review article
C2 - 19084097
AN - SCOPUS:57149142767
VL - 199
SP - 596
EP - 609
JO - American Journal of Obstetrics and Gynecology
JF - American Journal of Obstetrics and Gynecology
SN - 0002-9378
IS - 6
ER -